Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait

Medical Principles and Practice

Volumn 13, Issue 1, 2004, Pages 30-34

  Al Azemi, M ^a,b   Labib, N S ^b   Motawy, M M M ^c   Temmim, L ^c   Moussa, M A A ^a   Omu, A E ^a,b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b AL SABAH HOSPITAL   (Kuwait)

^c KUWAIT CANCER CONTROL CENTER   (Kuwait)

Author keywords

Breast cancer; Endometrial pathology; Screening; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KUWAIT; MEDICAL INSTRUMENTATION; POSTMENOPAUSE; PREVALENCE;

AGED; ANTICARCINOGENIC AGENTS; BIOPSY; BREAST NEOPLASMS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; FEMALE; HUMANS; KUWAIT; MIDDLE AGED; POLYPS; POSTMENOPAUSE; PREVALENCE; RECEPTORS, ESTROGEN; RISK FACTORS; TAMOXIFEN; TIME FACTORS; VACUUM CURETTAGE;

EID: 0344305695     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074048     Document Type: Article

References (21)

1. Paszko Z, Omar YT, Nasralla MY, Jazzaf H, Bouzubar L, Temmim L, Padzik H: Estrogen and progesterone receptor status in breast cancer in Kuwaiti female population. Neoplasma 1993;40:127-132.
2. Bartlett K, Eremin O, Hutcheon A, Preece P, Scott JS, Forrest P, Chetty U, Prescott RJ, Rodger A, Smyth J, George D, Habeshaw T, Kaye SB, McArdle CS, McCallum M, Smith DC, McMillan B, Robinson SM, Stewart HJ, White GK, Giles GR: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 1987;ii:171-175.
3. Boccardo F, Guarneri D, Rubagotti A, Casertelli GL, Bentivoglio G, Conte N, Campanella G, Gaggero G, Comelli G, Zanardi S, et al: Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori 1984;70:61-68.
4. Fisher B, Costantino JP, Redmond CK: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-537.
5. Hardell L: Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 1988;iii:563.
6. Fornander T, Rutqvist LE, Cedarmark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989;i:117-120.
7. Atlante G, Pozzi M, Vincenzoni C, Vocaturo G: Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 1990;37:378-380.
8. Malfetano JH: Tamoxifen associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 1990;39:82-84.
9. Mathew A, Chabon AB, Kabakow B, Drucker M, Hirschman RJ: Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. NY State J Med 1990;90:207-208.
10. Henderson IC: Should tamoxifen use be curtailed because of the risk of endometrial cancer? Breast Dis Year Book Q 1994;5:18-23.
11. Neven P, De Muyder X, Van Belle Y, Campo R, Vanderick G: Tamoxifen and the uterus (editorial). BMJ 1994;309:1313-1314.
12. Amy JJ, Van Liederkerke D: Gynaecological monitoring during tamoxifen therapy (letter). Lancet 1995;345:253-254.
13. Schwartz LB, Snyder J, Horan C, Porges RF, Nachtigall LE, Goldstein SR: The use of transvaginal ultrasound and saline infusion sono-hysteroscopy for the evaluation of asymptomatic postmenopausal breast cancer patients on tamoxifen. Ultrasound Obstet Gynecol 1998;11:48-53.
14. Ismail SM: Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994;47:827-833.
15. Benedet JL, Pecorelli S: Staging Classifications and Clinical Practice Guidelines of Gynecologic Cancers by the FIGO Committee on Gynecologic Oncology. Amsterdam, Elsevier, 2000.
16. Barakat RR, Gilewski TA, Almadrones L, Saigo PE, Venkatraman E, Hudis C, Hoskins WJ: Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study using office endometrial biopsy. J Clin Oncol 2000;18:3459-3463.
17. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T: Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-664.
18. Neven P, DeMuylder X, Van Belle Y, Vanderick G, De Muylder E: Tamoxifen and the uterus and endometrium. Lancet 1989;i:375-376.
19. Cohen I, Rosen DJ, Shapira J, Cordoba M, Gilboa S, Altaras MM, Yigael D, Beyth Y: Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 1993;100:567-570.
20. Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, Costa A: Effect of tamoxifen on endometrial proliferation. J Clin Oncol 1996;14:434-440.
21. Early Breast Cancer Trialists' Collaborative Group: Effects adjuvant of tamoxifen and cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988;319:1681-1692.